Alpha Teknova, Inc. Revenue Disclosure
Note 3. Revenue Recognition
Teknova has two primary product categories: Lab Essentials; and Clinical Solutions.
Lab Essentials
Teknova is a leader in providing highly complex chemical formulations for use in biological research and drug discovery. The Company’s core research products consist of commonly used, catalog solutions and customer-specified formulations. During discovery, the Company’s products are used regularly in small, bench-scale experiments. As customers optimize their processes and begin to scale up in volume, they tend to order more custom products. The Lab Essentials portion of Teknova's business includes: pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. Teknova's Lab Essentials products include essential formulations for common research applications and highly customized formulations for customer-specific applications in genomics and bioproduction.
Clinical Solutions
Teknova is ISO 13485:2016 certified, enabling the Company to meet the quality system regulation of products for use as components in diagnostic and therapeutic products manufactured by the Company’s customers. Teknova believes that its Clinical Solutions products are used in the production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The Clinical Solutions portion of our business includes: liquid microbial culture media and supplements for cellular expansion and molecular biology reagents for sample manipulation, resuspension, and purification.
Teknova’s revenue, disaggregated by product category, was as follows (in thousands):
|
|
For the Year Ended December 31, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Lab Essentials |
|
$ |
31,044 |
|
|
$ |
28,883 |
|
Clinical Solutions |
|
|
7,650 |
|
|
|
7,097 |
|
Other |
|
|
1,826 |
|
|
|
1,765 |
|
Total revenue |
|
$ |
40,520 |
|
|
$ |
37,745 |
|
Teknova’s revenue, disaggregated by geographic region, which is determined based on customer location, was as follows (in thousands):
|
|
For the Year Ended December 31, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
United States |
|
$ |
38,249 |
|
|
$ |
35,919 |
|
International |
|
|
2,271 |
|
|
|
1,826 |
|
Total revenue |
|
$ |
40,520 |
|
|
$ |
37,745 |
|
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 2, 2026 | Showing above |
| 2024 | Mar 7, 2025 | |
| 2023 | Mar 27, 2024 | |
| 2022 | Mar 30, 2023 | |
| 2021 | Mar 18, 2022 | |
About Revenue Disclosures
Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.
Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.